Latest News

Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

07 May 2021

NEW YORK & LONDON, May 7, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and CSO Dr. Kunwar Shailubhai...

Read more

Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

05 May 2021

  • Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either...

Read more

Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT

27 April 2021

NEW YORK and LONDON – 27 April 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO...

Read more

Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.

13 April 2021

Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market

Read more

Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

30 March 2021

New York/London, 30 March 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to announce that the U.S. Food and Drug...

Read more

Accustem Update

30 March 2021

NEW YORK and LONDON - 30 March 2021 - Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, is pleased to confirm that, in order to finalise the distribution...

Read more

Page 1 of 26 Next